Latest NAV & returns of RELIANCE CAPITAL ASSET MANAGEMENT LTD.

Reliance Pharma Fund - Direct Plan - Growth Plan

Add To Compare

NAV on August 16, 2019
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 2,344 cr
Turnover Ratio 69.34%
Expense Ratio 1.36%
Exit Load 1.00%if redeemed within
1 Years
0.00%if redeemed after 1 Years
Returns
  • 1M: -4.11%
  • 1Y: -8.45%
  • 3M: -3.30%
  • 3Y: 0.44%
  • 6M: -6.24%
  • 5Y: 6.96%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 14 years) Kinjal Desai (Since over 1 year)
ISIN INF204K01I50
Fund Family Reliance
P/E Ratio 27.85
P/B Ratio 3.40
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 5.55
Beta 0.80
R-Squared 89.48
Info Ratio 1.30
Tracking Err 5.82
Sortino -0.221
Sharpe -0.153
Std Dev 14.579
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

You will not receive any dividends. Your investments will get the largest benefit of compounding.

View Factsheet

-
Best Sector Healthcare Funds
NAME LATEST
NAV
RETURNS
1y    
FUND
ASSETS
Expense
RATIO
RISK
9.216 -2.98% 168 cr 1.15% -
10.082 -4.12% 334 cr 0.76% -
145.547 -8.45% 2,344 cr 1.36% -


Other plans of Reliance Pharma


Other Equity funds by Reliance